Article · Wikipedia archive · Last revised Jul 12, 2026

Relacorilant

Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Relacorilant is a glucocorticoid receptor antagonist.

Last revised
Jul 12, 2026
Read time
≈ 2 min
Length
365 w
Citations
13
Source
Wikipedia ↗
Relacorilant
Clinical data
Trade namesLifyorli
Other namesCORT-125134
AHFS/Drugs.comlifyorli
License data
Routes of
administration		By mouth
Drug classAntiglucocorticoid
ATC code
  • None
Legal status
Legal status
Identifiers
  • [(4aR)-1-(4-Fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC27H22F4N6O3S
Molar mass586.57 g·mol−1
3D model (JSmol)
  • CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
  • InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
  • Key:WANIDIGFXJFFEL-SANMLTNESA-N

Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.1 Relacorilant is a glucocorticoid receptor antagonist.1

The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.2

Relacorilant was approved for medical use in the United States in March 2026.23

Medical uses

Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.1

Adverse effects

The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.2 The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.2

History

Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.2 Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.2 The trial excluded participants who required chronic or frequent use of glucocorticoids.2 Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.2

References

References

  1. "Lifyorli- relacorilant kit". DailyMed. 26 March 2026. Retrieved 1 April 2026.
  2. "FDA approves relacorilant with nab-paclitaxel for platinum-resistant". U.S. Food and Drug Administration (FDA). 25 March 2026. Retrieved 5 April 2026. This article incorporates text from this source, which is in the public domain.
  3. Kansteiner F (25 March 2026). "Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer". Fierce Pharma. Retrieved 26 March 2026.
External links
  • Clinical trial number NCT05257408 for "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer" at ClinicalTrials.gov